Company Positioned for Growth Serving Life Sciences Industries

Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced that its board of directors has elected Dan Henry as Chairman of the Board, succeeding Mark Newcomer who will continue in his role as President and Chief Executive Officer.

“Dan brings decades of experience in fintech, payments and leadership strategy along with a deep understanding of Paysign’s business and long‑term goals,” said Mark Newcomer, President and CEO of Paysign. “His vision and insight will be critical as we continue to carry out our growth and innovation strategy. As chairman, he will play a key role in supporting the company’s mission to deliver integrated fintech and healthcare technology solutions that drive long‑term growth.”

“I’m honored to assume the role of chairman at such a pivotal time for Paysign,” said Mr. Henry. “The company’s position at the intersection of healthcare and fintech gives us a unique opportunity to drive meaningful innovation and shareholder value.”

Dan Henry has served on Paysign’s Board of Directors since 2018 and currently chairs the Executive Compensation Committee. He is a veteran fintech executive with over 30 years of leadership experience, including roles as Co‑founder, President & COO of Euronet Worldwide (NASDAQ: EEFT) and CEO of NetSpend Corporation, where he led its IPO in 2010 and negotiated its $1.4 billion acquisition by TSYS in 2013. Most recently, he was CEO of Green Dot Corporation (NYSE: GDOT), a leading provider of banking and payment solutions. He has also served on the boards of The Brinks Company, Rx Savings Solutions and Dama Financial. Mr. Henry holds a B.S. in Business Administration with majors in Finance, Economics and Real Estate from the University of Missouri.

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250814719350/en/